150 related articles for article (PubMed ID: 34254153)
41. Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen.
Salerno A; Picconi E; Genovese O; Piastra M; Pulitanò SM; Tosi F; Mancino A; Pane M; De Sanctis R; Carlini D; Mercuri EM; Conti G
Paediatr Anaesth; 2023 Apr; 33(4):282-290. PubMed ID: 36636888
[TBL] [Abstract][Full Text] [Related]
42. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
43. Delivery of Nusinersen Through an Ommaya Reservoir in Spinal Muscular Atrophy.
Iannaccone ST; Paul D; Castro D; Weprin B; Swift D
J Clin Neuromuscul Dis; 2021 Mar; 22(3):129-134. PubMed ID: 33595996
[TBL] [Abstract][Full Text] [Related]
44. Skip constructs in spinal muscular atrophy: outcomes of a novel approach for posterior spinal instrumentation and fusion.
Konigsberg MW; Matsumoto H; Ball JR; Roye BD; Vitale MG
Spine Deform; 2020 Oct; 8(5):1093-1097. PubMed ID: 32253736
[TBL] [Abstract][Full Text] [Related]
45. Administration of nusinersen via paramedian approach for spinal muscular atrophy.
Iwayama H; Wakao N; Kurahashi H; Kubota N; Hattori A; Kumagai T; Okumura A
Brain Dev; 2021 Jan; 43(1):121-126. PubMed ID: 32773161
[TBL] [Abstract][Full Text] [Related]
46. Ultrasound-guided nusinersen administration for spinal muscular atrophy patients with severe scoliosis: an observational study.
Zhang J; Cui X; Chen S; Dai Y; Huang Y; Zhang S
Orphanet J Rare Dis; 2021 Jun; 16(1):274. PubMed ID: 34120632
[TBL] [Abstract][Full Text] [Related]
47. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
48. Intrathecal Access Through Suboccipital Port in Patients With Spinal Muscular Atrophy and Complex Spines: Case Series and Technical Note.
Tran DK; Shah V; Muhonen MG
Cureus; 2020 Aug; 12(8):e9525. PubMed ID: 32905153
[TBL] [Abstract][Full Text] [Related]
49. Symptomatic intracranial hypertension in an adult patient with spinal muscular atrophy and arachnoid cysts receiving nusinersen.
Machetanz G; Grziwotz M; Semmler L; Maier M; Maegerlein C; Deschauer M
J Neuromuscul Dis; 2023; 10(4):719-725. PubMed ID: 37248913
[TBL] [Abstract][Full Text] [Related]
50. Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review.
Meylemans A; De Bleecker J
Acta Neurol Belg; 2019 Dec; 119(4):523-533. PubMed ID: 31388901
[TBL] [Abstract][Full Text] [Related]
51. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
Bielsky AR; Fuhr PG; Parsons JA; Yaster M
Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
[TBL] [Abstract][Full Text] [Related]
52. The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for "Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy" on page 650.
Dutta D; Chandra G; Mohanakumar KP
J Neurochem; 2020 Jun; 153(5):545-548. PubMed ID: 32128827
[TBL] [Abstract][Full Text] [Related]
53. Nusinersen: A Treatment for Spinal Muscular Atrophy.
Claborn MK; Stevens DL; Walker CK; Gildon BL
Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
[TBL] [Abstract][Full Text] [Related]
54. Intrathecal Administration of Nusinersen Using the Ommaya Reservoir in an Adult with 5q-Related Spinal Muscular Atrophy Type 1 and Severe Spinal Deformity.
Papaliagkas V; Foroglou N; Toulios P; Moschou M; Gavriilaki M; Notas K; Chatzikyriakou E; Zafeiridou G; Arnaoutoglou M; Kimiskidis VK
Case Rep Neurol; 2021; 13(3):710-715. PubMed ID: 34950009
[TBL] [Abstract][Full Text] [Related]
55. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
[TBL] [Abstract][Full Text] [Related]
56. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
[TBL] [Abstract][Full Text] [Related]
57. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
58. Procedural sedation for paediatric patients with spinal muscular atrophy undergoing intrathecal treatment.
Sever F; Özmert S; Arıbaş Öz N
Br J Clin Pharmacol; 2023 Aug; 89(8):2465-2471. PubMed ID: 36932845
[TBL] [Abstract][Full Text] [Related]
59. Intrathecal Administration of Nusinersen in Pediatric SMA Patients with and without Spine Deformities: Experiences and Challenges over 3 Years in a Single Center.
Johannsen J; Weiss D; Schlenker F; Groth M; Denecke J
Neuropediatrics; 2021 Jun; 52(3):179-185. PubMed ID: 33276405
[TBL] [Abstract][Full Text] [Related]
60. Nusinersen: A Review in 5q Spinal Muscular Atrophy.
Hoy SM
CNS Drugs; 2021 Dec; 35(12):1317-1328. PubMed ID: 34850360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
